Genprex Initiates Patient Dosing in Groundbreaking Clinical Trial
Genprex, Inc. (NASDAQ: GNPX), a pioneer in gene therapy, is proud to announce an exciting milestone: the enrollment and dosing of the first patient in the Phase 2 expansion of the Acclaim-3 clinical study. This significant phase involves Reqorsa® Gene Therapy, utilized in combination with Tecentriq® to provide maintenance treatment for patients battling extensive stage small cell lung cancer (ES-SCLC).
Expanding the Acclaim-3 Clinical Study
With an eye towards brighter futures for cancer patients, Genprex aims to enroll a total of 50 patients across 10 to 15 sites in the United States. The expansion phase seeks to evaluate the efficacy of the combination therapy over an 18-week period, focusing on the progression-free survival (PFS) rates of patients receiving these innovative treatments.
Importance of Progression-Free Survival
Progression-free survival is a critical measure in cancer research, as it indicates the length of time during and after treatment that a patient lives without the cancer worsening. The treatment of ES-SCLC presents unique challenges, with current median PFS rates not meeting patient needs. The combination of Reqorsa and Tecentriq represents a hopeful avenue to improve these statistics.
Genprex's Innovative Approach to Gene Therapy
The underpinnings of Genprex's research lie in the re-expression of tumor suppressor genes. Reqorsa is designed to introduce the TUSC2 gene back into cancer cells, which may be critical for combating the aggressive nature of SCLC. Early nonclinical studies suggest that re-expressing TUSC2 could enhance the effectiveness of Tecentriq, making this study potentially pivotal in improving patient outcomes.
Exciting Preliminary Data
Research presented at the recent October 2023 conference demonstrated that the Reqorsa and Tecentriq combination could control tumor burden more effectively than either drug alone. This crucial evidence supports Genprex's belief that their gene therapy can significantly improve cancer treatment paradigms going forward.
The Acclaim-3 Trial Overview
This multi-center, open-label clinical trial is at the forefront of cancer therapy. Participants are carefully selected for the study, particularly those who have shown stable disease after receiving preliminary treatments with Tecentriq and chemotherapy. This phase is essential to ascertain comprehensive data on the long-term effects of the gene therapy.
About Genprex, Inc.
Founded with the mission of changing lives, Genprex, Inc. specializes in creating innovative gene therapy solutions. Their cutting-edge technology allows for the administration of beneficial genes aimed at treating debilitating diseases such as cancer and diabetes. Collaborating with top institutions, the company strives to develop effective therapies for large populations, particularly where conventional treatments fall short.
Genprex's Commitment to Advancing Cancer Treatments
Through its rigorous research and dedication to patient well-being, Genprex continues to break new ground in the treatment of cancers. With its lead product, Reqorsa® Gene Therapy, undergoing multiple clinical trials, the company is positioned to offer significant improvements to cancer treatment standards.
Patient-Centric Innovations
Genprex’s approach is inherently patient-centered, focusing on the re-introduction of critical genes to cancer therapies. Their work with the Oncoprex® Delivery System exemplifies this commitment, allowing for targeted treatment using lipid-based nanoparticles to effectively package and deliver genes to tumor cells.
Frequently Asked Questions
What is the Acclaim-3 clinical trial?
The Acclaim-3 clinical trial focuses on evaluating the effectiveness of Reqorsa® Gene Therapy in combination with Tecentriq® for treating extensive stage small cell lung cancer (ES-SCLC).
How many patients will be enrolled in the study?
The Phase 2 expansion portion of the Acclaim-3 clinical trial will enroll a total of 50 patients across multiple sites in the U.S.
What does progression-free survival mean?
Progression-free survival (PFS) measures the duration during and after treatment that a patient lives without their cancer worsening, a crucial endpoint in evaluating cancer therapies.
How does Reqorsa work?
Reqorsa is designed to express the TUSC2 gene, a tumor suppressor, that may improve the efficacy of existing cancer therapies like Tecentriq.
What are the future plans for Genprex?
Genprex is committed to advancing its gene therapy programs, aiming to provide effective treatments for cancer and diabetes and continue developing innovative therapeutic applications.
